Managed care interventions for improving outcomes in acute heart failure syndromes.
暂无分享,去创建一个
M. Gheorghiade | G. Fonarow | J. Dunn | S. Khan | E. Pezalla
[1] G. Fonarow,et al. Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: A report from OPTIMIZE‐HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) * , 2008, European journal of heart failure.
[2] C. O'connor,et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2008, American heart journal.
[3] K. Swedberg,et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. , 2008, JAMA.
[4] R. Califf,et al. Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) , 2008, Circulation. Heart failure.
[5] David D. Shin,et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. , 2007, Archives of internal medicine.
[6] G. Fonarow,et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. , 2007, European heart journal.
[7] K. Swedberg,et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.
[8] K. Swedberg,et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.
[9] M. Guglin,et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.
[10] David D. Shin,et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. , 2007, The American journal of cardiology.
[11] Nancy M Albert,et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.
[12] J. Rouleau,et al. Navigating the Crossroads of Coronary Artery Disease and Heart Failure , 2006, Circulation.
[13] Carol R Horowitz,et al. Effects of Nurse Management on the Quality of Heart Failure Care in Minority Communities , 2006, Annals of Internal Medicine.
[14] Luigi Tavazzi,et al. Acute Heart Failure Syndromes: Current State and Framework for Future Research , 2005, Circulation.
[15] J. Ornato,et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .
[16] Harlan M Krumholz,et al. ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society , 2005, Circulation.
[17] A. Mebazaa,et al. The challenge of acute heart failure syndromes. , 2005, The American journal of cardiology.
[18] M. Nieminen. Pharmacological options for acute heart failure syndromes: current treatments and unmet needs , 2005 .
[19] W John Boscardin,et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.
[20] K. Adams,et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.
[21] Christopher M O'Connor,et al. Risk stratification after hospitalization for decompensated heart failure. , 2004, Journal of cardiac failure.
[22] Holly Rimmasch,et al. Improvements in 1-Year Cardiovascular Clinical Outcomes Associated with a Hospital-Based Discharge Medication Program , 2004, Annals of Internal Medicine.
[23] Kamyar Kalantar-Zadeh,et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. , 2004, Journal of the American College of Cardiology.
[24] M. Gheorghiade,et al. Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial , 2003, Circulation.
[25] T. Speroff,et al. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. , 2003, The American journal of medicine.
[26] S. Silver,et al. Heart Failure , 1937, The New England journal of medicine.
[27] R. Maestri,et al. Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care , 2002 .
[28] A. Gawlinski,et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). , 2001, The American journal of cardiology.
[29] S. Yusuf,et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. , 1994, Journal of the American College of Cardiology.
[30] Abraham Wt,et al. Body fluid volume regulation in health and disease. , 1994 .
[31] M. Packer,et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. , 1984, The New England journal of medicine.